Sugi Predict

Sugi Predict / Targets / KCNA5

KCNA5

Potassium voltage-gated channel subfamily A member 5 · P22460 · KCNA5 on Sugi Atlas →

71,178 patent compounds predicted against KCNA5, 36,103 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL211697 SCHEMBL211697 0.53 13/20
SCHEMBL210449 SCHEMBL210449 0.59 12/20
SCHEMBL184864 SCHEMBL184864 0.59 11/20
SCHEMBL185078 SCHEMBL185078 0.50 11/20
SCHEMBL208782 SCHEMBL208782 0.55 10/20
SCHEMBL411158 SCHEMBL411158 0.70 9/20
SCHEMBL409729 SCHEMBL409729 0.69 9/20
SCHEMBL409666 SCHEMBL409666 0.65 9/20
SCHEMBL409667 SCHEMBL409667 0.65 9/20
SCHEMBL409675 SCHEMBL409675 0.65 9/20
SCHEMBL410119 SCHEMBL410119 0.65 9/20
SCHEMBL210005 SCHEMBL210005 0.51 9/20
SCHEMBL379387 SCHEMBL379387 0.49 9/20
SCHEMBL210527 SCHEMBL210527 0.64 8/20
SCHEMBL432115 SCHEMBL432115 0.64 8/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL207813) 0.58 8/20
SCHEMBL283636 SCHEMBL283636 0.52 8/20
SCHEMBL128718 SCHEMBL128718 0.51 8/20
SCHEMBL364905 SCHEMBL364905 0.50 8/20
Bergaptol Bergaptol (SCHEMBL194016) 0.51 7/20

Clinical trials — most relevant to KCNA5 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery PHASE4RECRUITING
Role of Eplerenone in Reducing Recurrence of Atrial Fibrillation in Patient With Structural Heart Disease PHASE4NOT_YET_RECRUITING
Evaluation of Efficacy and Safety of THRV-1268 in Long QT Syndrome Type 2 (LQTS 2) PHASE2/PHASE3RECRUITING
Mutation-specific Therapy for the Long QT Syndrome PHASE2COMPLETED
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients PHASE2COMPLETED
N-of-1 in ATS and MEPPC PHASE2NOT_YET_RECRUITING
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy PHASE1/PHASE2RECRUITING
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK PHASE1COMPLETED
A First-in-Human SAD and MAD Study in Healthy Participants to Evaluate Oral YR011 Tablet PHASE1NOT_YET_RECRUITING
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
Qatar Cardiovascular Biorepository of AF Patients nanUNKNOWN
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism nanCOMPLETED
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA) nanUNKNOWN
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats nanCOMPLETED
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats nanCOMPLETED
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Prospective Identification of Long QT Syndrome in Fetal Life nanCOMPLETED
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study nanUNKNOWN
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia nanUNKNOWN
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. nanUNKNOWN
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy nanUNKNOWN
Characteristics of Episodic Ataxia Syndrome nanCOMPLETED
Worm Study: Modifier Genes in Sudden Cardiac Death nanUNKNOWN
The Use of Antiarrhythmic Drugs in Pediatrics nanUNKNOWN
Role of SNP and DIGOXIN Response in Atrial Fibrillation Patients nanCOMPLETED
Identify the Genes Polymorphisms Related to Non-familial Bradyarrhythmia nanUNKNOWN
Development of an Artificial Intelligence Algorithm to Detect Pathological Repolarization Disorders on the ECG and the Risk of Ventricular Arrhythmias nanRECRUITING
Gene Study for Infantile Onset Diabetes nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a KCNA5 binder may also engage these)

ProteinNameSimilarity
P50638 — 1.000 P50638 →
Q61762 — 1.000 Q61762 →
P19024 — 1.000 P19024 →
P17659 — 1.000 P17659 →
P79197 — 0.999 P79197 →
KCNA6 Potassium voltage-gated channel subfamily A member 6 0.998 landscape →
KCNA3 Potassium voltage-gated channel subfamily A member 3 0.993 landscape →
P25122 — 0.992 P25122 →
Q63734 — 0.992 Q63734 →
Q03721 — 0.992 Q03721 →
Q61923 — 0.992 Q61923 →
Q96PR1 — 0.990 Q96PR1 →
Q14B80 — 0.990 Q14B80 →
CACNA1H Voltage-dependent T-type calcium channel subunit alpha-1H 0.990 landscape →
P16390 — 0.989 P16390 →
Q95167 — 0.988 Q95167 →
KCNH3 Voltage-gated inwardly rectifying potassium channel KCNH3 0.988 landscape →
P22462 — 0.988 P22462 →
P15384 — 0.987 P15384 →
Q9TUI4 — 0.987 Q9TUI4 →
A4K2P6 — 0.987 A4K2P6 →
KCNA2 Potassium voltage-gated channel subfamily A member 2 0.986 landscape →
P15385 — 0.986 P15385 →
A6H8H5 — 0.986 A6H8H5 →
A4K2M4 — 0.986 A4K2M4 →
Q63099 — 0.986 Q63099 →
Q03719 — 0.986 Q03719 →
Q9TTJ7 — 0.986 Q9TTJ7 →
O89047 — 0.986 O89047 →
Q61423 — 0.985 Q61423 →